NCT03210662View on ClinicalTrials.gov

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Aggressive Non-Hodgkin LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Aggressive Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaTransformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
RADIATION

External Beam Radiation Therapy

Undergo EBRT

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER